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Abstract  10 
It is estimated that more than 2.5 million individuals worldwide have multiple sclerosis (MS). MS is an 11 
autoimmune neurodegenerative disease resulting from the destruction of the myelin sheath that enwraps 12 
axons driven by an immune cell attack to the central nervous system. Current therapeutic programs for 13 
MS focus in immunosuppression and more recently in the use of immunomodulatory molecules. These 14 
therapeutic approaches provide significant improvements in the management of the disease, but are 15 
frequently associated with an increased susceptibility of opportunistic infection. In this commentary, we 16 
highlight the application of nano and micro-technologies as emerging and innovative solutions for MS 17 
therapy with the potential to restore immune homeostasis via antigen-specific interactions. Furthermore, 18 
we propose and discuss the usage of a minimally invasive approach, namely microneedle patches, as a 19 
new therapeutic route. 20 
 21 
 22 
 23 
Microneedle patches for the delivery of specific antigens to restore immunotolerance in the 24 
context of Multiple Sclerosis. 25 
 26 
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1. Multiple Sclerosis: etiology and current therapeutics 31 
Multiple sclerosis (MS) is a chronic immune mediated demyelinating disease of the central nervous 32 
system (CNS) caused by a strong T cell attack directed towards proteins of the myelin sheath enwrapping 33 
CNS axons; this ultimately culminates in demyelination and neuronal degeneration [1, 2]. In developed 34 
countries it is the second cause of neurological disability in young adults, with high burden for the patient, 35 
the family and the resources of the health system [3]. It is a complex disease and its underlying 36 
mechanisms are only partially understood. Most patients initially present with a clinically isolated 37 
syndrome (CIS). These CIS patients experience an acute episode, which typically affects one brain 38 
region, being the clinical symptoms variable depending on the involvement of motor, sensory, visual or 39 
autonomic systems [4]. Some CIS patients will evolve to definite MS disease, while others won’t. 40 
Nowadays, the diagnosis of definite MS is based on recognized clinical criteria, with the support of 41 
magnetic resonance imaging (MRI) data and cerebrospinal fluid (CSF) analysis [2], and can only be done 42 
when there is dissemination of neurologic dysfunction in space and time [2, 4, 5], and after differential 43 
diagnosis is excluded [5]. Concerning the MRI findings, the presence of multifocal demyelinating lesions 44 
at different timepoints involving preferentially the periventricular white matter, the brain stem, the 45 
cerebellum and the spinal cord are indicative of MS [2]. Furthermore, the presence of oligoclonal bands or 46 
increased concentration of immunoglobulin (Ig)G in the patients’ CSF are widely used to support MS 47 
diagnosis, but are not MS- specific [2, 6].  48 
Patients with definite MS can develop different profiles of the disease, being classified as relapse-49 
remitting (RR)-MS, primary progressive (PP)-MS or secondary progressive (SP)-MS. RR-MS represents 50 
about 80-85% of MS cases [7] and is characterized by transient symptoms (relapse) that often improve 51 
within weeks (remission). However, the ability to fully recover from relapse episodes diminishes with time, 52 
and irreversible damage accumulates in the CNS, giving rise to SP-MS. The remaining 15-20% of 53 
patients has PP-MS, and does not show this relapse-remitting pattern; rather, their symptoms become 54 
gradually worst along the course of the disease.  55 
MS is nowadays a treatable, although not curable, disease. The first proven MS treatments were 56 
approved in the nineties and consisted in different formulations of interferon-1 administered 57 
intramuscularly or subcutaneously. Although a major breakthrough at the time and still an important part 58 
of treatment options today, given their excellent safety, interferon-1 based treatments are only moderately 59 
efficacious, leading to full control of the disease in only a small percentage of patients [8]. Interferons 60 
have pleiotropic effects, including a reduced T-cell entry into the CNS [9]. Glatiramer acetate is a mixture 61 
of oligopeptides designed to mimic the aminoacid composition of myelin that induces a skew towards a 62 
regulatory response. Also administered subcutaneously, it has an efficacy similar to interferons and an 63 
excellent safety record that make it still an important player in MS treatment options [8].  64 
Recently the portfolio of approved MS treatments was enriched by more options that encircle two major 65 
therapeutic approaches targeting either T-cells or B-cells. Concerning T-cells modulation a collection of 66 
drugs is currently being applied in the clinical setting, with moderate success, as next described. 67 
Teriflunomide is an oral medication that interferes with the fast expansion of recently activated 68 
lymphocytes, preserving the basal proliferation of memory cells. It has a moderate efficacy, similar to 69 
interferons, but some safety concerns, including teratogenic potential [10]. Dymethylfumarate is an oral 70 
treatment with a putative dual mechanism of action, including immunosuppression and neuroprotection. 71 
In clinical trials it demonstrated a good efficacy in controlling the disease but concerns regarding its long-72 
term safety, particularly the profound lymphopenia and the risk of a serious opportunistic CNS infection, 73 
progressive multifocal leukoencephalopathy (PML), might limit its use [11]. Fingolimod, a functional 74 
antagonist of S1P receptors that blocks lymphocyte egress from lymph nodes [12], has also a good 75 
efficacy but similar concerns over lymphopenia and PML [8]. Natalizumab is a highly efficacious 76 
monoclonal antibody that blocks lymphocyte entry into the CNS; however, it is associated with a high risk 77 
of PML in patients which have antibodies against the causing organism, JC virus, which almost limits its 78 
use to seronegative patients representing less than half of MS patients [13].  79 
While all the above-mentioned drugs interfere with T-cell function, alternatively, ocrelizumab is a 80 
monoclonal antibody that destroys B-cells and, surprisingly, was shown to have a good efficacy in MS 81 
patients [14]. Although not yet approved, it has forced a major revision of MS pathogenesis to take into 82 
account the role of B-cells, which are not only seen as antibody producers but also as antigen presenting 83 
and cytokine releasing cells, able to activate Th1 and Th17 responses and induce pathology [15]. 84 
Although data are still preliminary, ocrelizumab may increase the risk of serious infections, including PML, 85 
which might limit its use. Targeting both B and T cells, alemtuzumab is a monoclonal antibody that 86 
induces a severe depletion of circulating lymphocytes and is said to “reset” the immune system [16]. 87 
Upon immune reconstitution, alemtuzumab-treated patients are able to stay disease free for periods of up 88 
to 5 years (longer follow-ups are still scarce), in what represents a first step towards an effective cure [16]. 89 
However, such efficacy comes at the cost of an increased risk of serious infections in the first weeks, 90 
requiring antibiotic profilaxis and precautions, and a significantly higher risk of autoimmune disturbances 91 
in the following years [16]. 92 
As can be gleaned from the above, MS treatments are in an exciting era, with several new options being 93 
approved, many more in the pipeline, and new drug targets and modes of action being available. More 94 
importantly, some treatments have been shown to allow a reset of the immune system, which might make 95 
a cure even more reachable than before. However, we weren’t able, so far, of breaking the close ties 96 
between efficacy and risk. These severely limit the use of more efficacious medications in all patients and 97 
the extension of their benefits to all patients. Thus, the finding of a highly efficacious and safe therapeutic 98 
is still an unmet medical need. This paves the way for nanotechnology-based approaches. 99 
 100 
2. Nanoengineered systems for MS therapeutics 101 
The use of nanotechnology and in particular of nanoparticles has been actively investigated for the 102 
development of new therapies for MS. Taking advantage of their size, nanoparticles are easily 103 
internalized by the cells, being suitable carriers for drugs, immunomodulatory molecules or antigens. The 104 
use of materials at the nanoscale is expected to provide unique opportunities to improve drug solubility 105 
and bioavailability, allowing targeted delivery, controlled release and consequently more effective routes 106 
of administration and lower toxicity [17]. Interestingly, not only nanoparticles can serve as carriers of 107 
relevant molecules as they can also trigger an immunomodulatory effect. In fact, variations in the 108 
chemical composition, size and shape of nanoparticles differentially impact the immune response [18] 109 
[19], which might be even more significant in the context of autoimmune diseases [20]. 110 
In MS, the use of nanoparticles has been investigated within two major applications: 1) as drug delivery 111 
systems, and 2) as vectors for antigen-specific immunomodulation. Nanoparticles can bring new solutions 112 
for the delivery of drugs that specifically target the immune or the neurodegenerative aspects of MS. 113 
Recent reports describe the encapsulation in liposomal formulations of immunomodulatory drugs 114 
currently applied in MS therapeutics such as methylprednisolone [21] or fingolimod [22]. These nano-115 
sized formulations showed a higher efficiency in a MS animal model due to improved pharmacokinetics 116 
and biodistribution when compared to the free drugs. Focusing in reducing neurodegeneration, polymeric 117 
nanoparticles targeted to oligodendrocyte precursor cells were applied to deliver leukaemia inhibitory 118 
factor (LIF) and to successfully promote remyelinization [23].  119 
Importantly, nanoparticles have also been explored as vectors for antigen-specific immunomodulation. 120 
The delivery of autoantigens related with the autoimmune response in MS is expected to allow the 121 
specific blockade of the damaging effects of self-reactive immune-cell function while maintaining the 122 
ability of the immune system to clear non-self antigens, thus restoring immunotolerance. This “tolerant 123 
approach” was firstly tested by the administration of soluble autoantigens, but the massive amounts of 124 
antigen required [24] along with some reported cases of anaphylactic response [25] prompt the need for 125 
new and safer solutions. The administration of peptides crosslinked to splenic leucocytes demonstrated 126 
very promising results, inducing a robust antigen-specific tolerance [26, 27]. Nonetheless, in order to 127 
circumvent the use of cellular components and the drawbacks associated, like cost and manipulation, 128 
researchers have been focused in the development of alternative strategies based on nanoparticulate 129 
systems. The premise is that nanoparticles crosslinked with disease-associated antigens and their 130 
epitopes can target antigen-presenting cells (APCs) capable to regulate T cell function and 131 
simultaneously support the induction and/or expansion of regulatory T cells (Tregs), restoring 132 
immunological tolerance. 133 
The intravenous administration of poly(D,L-lactide-co-glycolide) (PLGA) microparticles crosslinked with 134 
proteolipid protein (PLP)139-151 peptide (the immunodominant T cell myelin epitope in SJL mice from the 135 
myelin most abundant protein - PLP) showed remarkable results, being able not only to reduce the 136 
clinical score if administrated prophylactically, but also to treat ongoing disease [28]. Interestingly, PLP139-137 
151 administrated in the form of colloidal hydrogel demonstrated to be effective only if administrated before 138 
the disease onset [29]. The use of poly(ethylene-co-maleic acid) (PEMA) as surfactant allowed the 139 
preparation of PLGA nanoparticles and provided a reliable platform for different antigen crosslinking, as 140 
demonstrated by the relevant results in the induction of immunological tolerance both in the context of 141 
experimental autoimmune encephalomyelitis (EAE), the animal model for MS [30] and in a transplantation 142 
model [31]. 143 
Alternatively to antigen crosslinking, nanoparticles can be loaded with the antigen of interest. This 144 
concept can be extended to the development of multifunctional systems that combine the delivery of 145 
antigens with other molecules/drugs as a mean to turn the immune response more specific and/or more 146 
effective. Loading gold nanoparticles with the T-cell epitope from myelin oligodendrocyte glycoprotein 147 
(MOG35-55) and ITE (2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester - a tolerogenic 148 
molecule) showed to induce functional regulatory T cells in an EAE animal model more efficiently than 149 
MOG-loaded particles [32]. PLGA nanoparticles containing MOG35-55 and interleukin-10 (IL-10) mediate a 150 
sustained release of the molecules [33] and, although the results in terms of regulatory T cells expansion 151 
were not as impressive as the obtained for crosslinked nanoparticles, it was shown that the severity of the 152 
disease can be reduced via subcutaneous administration of the particles. In the PLP-associated EAE 153 
model, the use of rapamycin, an immunosuppressant molecule, loaded in PLGA nanoparticles along with 154 
PLP139-151 peptide promoted complete inhibition of disease relapses after both intravenous and 155 
subcutaneous administration [34].   156 
The results achieved so far using nanoparticles to induce immunotolerance are promising and should 157 
soon initiate clinical trials. A further step towards the use of nanoparticles to induce immunotolerance 158 
might be achieved when combined with alternative and minimally invasive routes of administration, which 159 
will next be explored. 160 
 161 
 162 
3.  A microneedle-based immunotolerance approach for MS 163 
Microneedles have been extensively investigated in the recent years as mean to mediate the delivery of 164 
drugs and/or antigens to the epidermal and/or intradermal space, overcoming the skin stratum corneum 165 
barrier. These devices hold the potential of allowing self-administration and painless application. 166 
Moreover, microneedle devices can be designed to dissolve in the skin, eliminating the issue of 167 
microneedle remaining and removal from the skin and allowing a safe disposal without biohazardous 168 
waste [35]. 169 
Although microneedles show great promise for the delivery of drugs [36] and also as sensing devices 170 
[37], it is in the research area of vaccines that they showed, so far, more advances. It was demonstrated 171 
that vaccination using microneedles triggers stronger immune responses comparing to conventional 172 
injection procedures, allowing sparing of antigens [38]. Indeed, the use of microneedle-based devices for 173 
influenza vaccination is currently under clinical trials.   174 
The improved antigen immunogenicity using microneedle devices is considered to be related to the 175 
delivery of antigens at the epidermal and intradermal layer of the skin. The skin is highly rich in 176 
immunologically active APCs, which deliver antigens to the proximal lymph nodes where T and B cells are 177 
activated, triggering the immune response [39]. Also, in the skin (particularly at the epidermis and the 178 
epithelium from the hair follicles) monocytes and Langerhans cells are abundant. Langerhans cells 179 
display intrinsic tolerogenic properties in vivo [40]. Moreover, a small trial enrolling 14 MS patients 180 
showed that the passive diffusion of myelin-related peptides through the skin induces some 181 
improvements in the disease, namely reducing the incidence of relapses and the area of lesion (assessed 182 
by MRI) [41]. These findings highlight the potential of this route of administration in immunotolerance-183 
based therapies.  184 
 185 
Overall, it is clear that therapeutics based on immunotolerance will take remarkable benefit from the 186 
application of micro and nano- technological knowledge. Nanoparticle design can assure antigen-specific 187 
response, targeted delivery and controlled dosing; whereas microneedle devices, as we propose, open 188 
the unique opportunity for sustained intradermal delivery, further contributing to an antigen-specific 189 
response and a tolerogenic effect in a minimally invasive therapeutic approach for MS.  190 
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